Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cost analysis of CYP2C19 genetic testing in percutaneous coronary intervention patients.

The pharmacogenomics journal - 8 Oct 2024

Huxley Samuel, Moriarty James, Hlatky Mark A, Lennon Ryan, Bailey Kent, Bell Malcolm, Geller Nancy, Lerman Amir, Mathew Verghese, Rosenberg Yves, Farkouh Michael, Rihal Charanjit, Borah Bijan, Pereira Naveen L

Abstract excerpt

CYP2C19 loss of function (LOF) carriers undergoing percutaneous coronary intervention (PCI) have an increased risk of ischemic events when treated with clopidogrel. PCI patients in TAILOR-PCI were randomized to clopidogrel or genotype-guided (GG) therapy in which LOF carriers received ticagrelor and non-carriers clopidogrel. Direct medical costs associated with a GG approach have not been described before....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenosine
Share to Clopidogrel

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Costs and Cost Analysis

Share to Percutaneous Coronary Intervention

Share to Pharmacogenomic Testing

Share to Pharmacogenomic Variants

Share to Ticagrelor

Share to Ticlopidine

Source

Identifiers

PMID: 39379363
DOI: 10.1038/s41397-024-00353-y

Genes

CYP2C19

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cost analysis of CYP2C19 genetic testing in percutaneous coronary intervention patients.PMID 39379363Read ↗

Cost-effectiveness of using CYP2C19 genotype to guide selection of clopidogrel or ticagrelor in Australia.Semantic proximity Read ↗

Review of pharmacoeconomic evaluation of genotype-guided antiplatelet therapy.Semantic proximity Read ↗

Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis.Semantic proximity Read ↗

CYP2C19 genotype plus platelet reactivity-guided antiplatelet therapy in acute coronary syndrome patients: a decision analysis.Semantic proximity Read ↗

Clopidogrel PharmacogeneticsSemantic proximity Read ↗

Short- and long-term cost-effectiveness analysis of CYP2C19 genotype-guided therapy, universal clopidogrel, versus universal ticagrelor in post-percutaneous coronary intervention patients in Qatar.Semantic proximity Read ↗

CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings.Semantic proximity Read ↗

CYP2C19 genotype-guided antiplatelet therapy: promises and pitfalls.Semantic proximity Read ↗

Clinical and cost-effectiveness of clopidogrel resistance genotype testing after ischaemic stroke or transient ischaemic attack: a systematic review and economic model.Semantic proximity Read ↗

Financial Analysis of CYP2C19 Genotyping in Patients Receiving Dual Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention.Semantic proximity Read ↗

Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome.Semantic proximity Read ↗

Implementing CYP2C19 Pharmacogenetic Testing for Personalized Antiplatelet Therapy: Findings From the QPGx-CARES Initiative.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.